Table 4. . Molecular subtype for Colorectal Cancer Subtyping Consortium.
| Subtype | Mutation | Copy number alteration | Activated pathway | Protein expression |
|---|---|---|---|---|
| CMS1 MSI immune (14%) |
Hypermutation BRAF mutation |
Low |
Immune pathway |
DNA repair, cell cycle, apotosis, inflammation |
| CMS2 Canonical (37%) |
Low mutated TP53 mutation |
High EGFR amplification |
WNT, MYC and epithelial pathway |
β-catenin |
| CMS3 Metabolic (13%) |
Intermediate mutated KRAS, PIK3CA mutation |
Intermediate |
Epithelial pathway |
β-catenin, receptors, IGFBP2 |
| CMS4 Mesenchymal (23%) | Low mutated | High | Mesenchymal, TGF-β, stromal, VEGF | NOTCH3, VEGFR2, fibronectin |
MSI: Microsatellite instability.